428 related articles for article (PubMed ID: 33584072)
1. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
[TBL] [Abstract][Full Text] [Related]
3. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
5. [Qualitative pathological assessment of liver fibrosis regression after antiviral therapy in patients with chronic hepatitis B].
Sun YM; Zhou JL; Wang L; Wu XN; Chen YP; Piao HX; Lu LG; Jiang W; Xu YQ; Feng B; Nan YM; Xie W; Chen GF; Zheng HW; Li H; Ding HG; Liu H; Lyu FD; Shao C; Wang TL; Ou XJ; Wang BQ; Chen SY; You H; Jia JD
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):819-826. PubMed ID: 29325275
[No Abstract] [Full Text] [Related]
6. Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents.
Putra J; Schiano TD; Fiel MI
Histopathology; 2018 May; 72(6):990-996. PubMed ID: 29235144
[TBL] [Abstract][Full Text] [Related]
7. Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response.
Chu CY; Cheng CH; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
J Formos Med Assoc; 2019 Jul; 118(7):1129-1137. PubMed ID: 30472042
[TBL] [Abstract][Full Text] [Related]
8. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
9. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
Chang X; Lv C; Wang B; Wang J; Song Z; An L; Chen S; Chen Y; Shang Q; Yu Z; Tan L; Li Q; Liu H; Jiang L; Xiao G; Chen L; Lu W; Hu X; Dong Z; Chen Y; Sun Y; Wang X; Li Z; Chen D; You H; Jia J; Yang Y
Hepatology; 2024 Feb; 79(2):425-437. PubMed ID: 37611260
[TBL] [Abstract][Full Text] [Related]
10. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
11. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
[TBL] [Abstract][Full Text] [Related]
12. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
[TBL] [Abstract][Full Text] [Related]
13. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
14. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Maylin S; Martinot-Peignoux M; Moucari R; Boyer N; Ripault MP; Cazals-Hatem D; Giuily N; Castelnau C; Cardoso AC; Asselah T; Féray C; Nicolas-Chanoine MH; Bedossa P; Marcellin P
Gastroenterology; 2008 Sep; 135(3):821-9. PubMed ID: 18593587
[TBL] [Abstract][Full Text] [Related]
15. [Long-term therapeutic effects and liver fibrosis changes with direct-antiviral therapy in HIV/HCV co-infected patients].
Liao BL; Li LH; Zhong HL; Li H; Li YH; Chen SZ; Wen CY; Hu FY; Lan Y; Cai WP
Zhonghua Gan Zang Bing Za Zhi; 2021 Aug; 29(8):776-780. PubMed ID: 34517460
[No Abstract] [Full Text] [Related]
16. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis improvement in patients with HCV treated with direct-acting antivirals.
McPhail J; Sims OT; Guo Y; Wooten D; Herndon JS; Massoud OI
Eur J Gastroenterol Hepatol; 2021 Jul; 33(7):996-1000. PubMed ID: 32639414
[TBL] [Abstract][Full Text] [Related]
19. Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events.
Sun Y; Chen W; Chen S; Wu X; Zhang X; Zhang L; Zhao H; Xu M; Chen Y; Piao H; Li P; Li L; Jiang W; Li X; Xing H; Liu X; Zhang Y; Wang B; Zhou J; Meng T; Zhao X; Shao C; Kong Y; Zhao X; Ou X; Liu C; Jia J; You H
Clin Gastroenterol Hepatol; 2024 Mar; 22(3):591-601.e3. PubMed ID: 38040276
[TBL] [Abstract][Full Text] [Related]
20. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
